Tozasertib (VX-680, MK-0457)

For research use only.

Catalog No.S1048

87 publications

Tozasertib (VX-680, MK-0457) Chemical Structure

CAS No. 639089-54-6

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. The only exceptions are Fms-related tyrosine kinase-3 (FLT-3) and c-ABL tyrosine kinase, which are inhibited by the Tozasertib with Ki of 30 nM and 20 nM, respectively. Tozasertib induces apoptosis and autophagy. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 134 In stock
USD 147 In stock
USD 370 In stock
USD 470 In stock
USD 527 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Tozasertib (VX-680, MK-0457) has been cited by 87 publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. The only exceptions are Fms-related tyrosine kinase-3 (FLT-3) and c-ABL tyrosine kinase, which are inhibited by the Tozasertib with Ki of 30 nM and 20 nM, respectively. Tozasertib induces apoptosis and autophagy. Phase 2.
Targets
Aurora A [1]
(Cell-free assay)		 Aurora C [1]
(Cell-free assay)		 Aurora B [1]
(Cell-free assay)		 FLT3 [4]
(Cell-free assay)		 Bcr-Abl [4]
(Cell-free assay)
0.6 nM(Ki app) 4.6 nM(Ki app) 18 nM(Ki app) 30 nM(Ki) 30 nM(Ki)
In vitro

Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150  nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12  hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. [2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BE-13 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn0TZZKSzVyPUCuNFA{OzhizszN NHLWcW5USU6JUlXS
RS4-11 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P5c2lEPTB;MD6wNFQxPCEQvF2= M2DaR3NCVkeURWK=
MFH-ino MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17VdmlEPTB;MD6wNFk6KM7:TR?= NHq2d2JUSU6JUlXS
NTERA-S-cl-D1 NEfxbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMEG0N|Qh|ryP NFPxUIFUSU6JUlXS
697 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi5SIt5UUN3ME2wMlAzPDdzIN88US=> NG\Cb4ZUSU6JUlXS
NALM-6 M{\IXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEi3SZRKSzVyPUCuNFI2PTJizszN NFLOTpZUSU6JUlXS
ES8 M3H0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXXdYZKSzVyPUCuNFQ3OTNizszN NYLWOG0{W0GQR2LFVi=>
HUTU-80 NWTUUXczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z6ZWlEPTB;MD6wOVI6QSEQvF2= MW\TRW5IWkWU
MV-4-11 M3LvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvTcZNKSzVyPUCuNFc4QDJizszN NVzwbotkW0GQR2LFVi=>
MONO-MAC-6 M1PzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;y[3hKSzVyPUCuNFc5PzlizszN MoryV2FPT1KHUh?=
LC-2-ad NUPWZ|JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;IS3hKSzVyPUCuNFg4QDlizszN NWW5TWVVW0GQR2LFVi=>
BL-41 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfM[GtKSzVyPUCuNVA1PDVizszN NVGxVnQyW0GQR2LFVi=>
A4-Fuk M2C5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL3R49KSzVyPUCuNVE2PjNizszN M3v4XHNCVkeURWK=
SW954 M1\xUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMUKyNlkh|ryP NXXk[5ZQW0GQR2LFVi=>
BV-173 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMUK2OFEh|ryP NEXqNFlUSU6JUlXS
TE-11 M3nDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMUS5PFIh|ryP NWftPVFSW0GQR2LFVi=>
SK-UT-1 NULTeItTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjITY9sUUN3ME2wMlE2QTZ3IN88US=> NF76Om1USU6JUlXS
SIG-M5 NFvjUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPyO4dKSzVyPUCuNVY4ODdizszN M33jVnNCVkeURWK=
OCUB-M M33DdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTkUnpwUUN3ME2wMlE3QTh|IN88US=> NWnPOVZUW0GQR2LFVi=>
K052 M1jhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi1VWRKSzVyPUCuNVk1QCEQvF2= MX7TRW5IWkWU
VA-ES-BJ NFyzWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S2T2lEPTB;MD6yNFA5PiEQvF2= NWO4b5Y4W0GQR2LFVi=>
SW982 NU\jZ2tGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPGW|ZKSzVyPUCuNlE{QCEQvF2= NV3VdWVWW0GQR2LFVi=>
LB647-SCLC NFvofI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jBNGlEPTB;MD6yNVUzOyEQvF2= NXjqWnNyW0GQR2LFVi=>
PSN1 M{TwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMkKwNlYh|ryP M4m2NXNCVkeURWK=
BB30-HNC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zSNGlEPTB;MD6yNlU6OSEQvF2= MXLTRW5IWkWU
ST486 M2TtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETHPWJKSzVyPUCuNlMxQDdizszN NIPXO29USU6JUlXS
MOLT-4 M371U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLJTWM2OD1yLkKzN|M4KM7:TR?= NHLPcJNUSU6JUlXS
EW-16 M{HMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K4emlEPTB;MD6yN|c3QCEQvF2= NHnIWY5USU6JUlXS
KS-1 NIPrU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jUTmlEPTB;MD6yN|c5PSEQvF2= Mo\2V2FPT1KHUh?=
SR NGT5UIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTzTWM2OD1yLkK0OVY1KM7:TR?= MknuV2FPT1KHUh?=
KM12 NGDK[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMk[zOkDPxE1? NXXVT3I{W0GQR2LFVi=>
EM-2 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMk[2OFEh|ryP MmK0V2FPT1KHUh?=
MEG-01 NU\zdpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS5TWM2OD1yLkK3PFQ6KM7:TR?= Mor3V2FPT1KHUh?=
NB13 NHPObYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2yPHVKSzVyPUCuNlc6QDRizszN M{\kZXNCVkeURWK=
RKO MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwM{C4NVMh|ryP MVXTRW5IWkWU
CESS MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rWTGlEPTB;MD6zNVMzQCEQvF2= Ml;BV2FPT1KHUh?=
EoL-1-cell M1ziSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfKV2huUUN3ME2wMlM{PDV7IN88US=> NFzTSHVUSU6JUlXS
DOHH-2 NVfGPYJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn6bY5NUUN3ME2wMlM{PzhzIN88US=> M2m1dnNCVkeURWK=
A388 NH\EfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwM{SwPFYh|ryP NICwZm9USU6JUlXS
LAMA-84 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D2fWlEPTB;MD6zOVE4QCEQvF2= NGfrZ2RUSU6JUlXS
IMR-5 M3HXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwM{W1OEDPxE1? NXHhdlJxW0GQR2LFVi=>
KARPAS-422 M3H6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny2TWM2OD1yLkO3NlczKM7:TR?= MVTTRW5IWkWU
MRK-nu-1 M3HkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\ZV2lEPTB;MD6zPFE{KM7:TR?= NXqw[FR7W0GQR2LFVi=>
BL-70 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnCdJFyUUN3ME2wMlM5QTd2IN88US=> NV7IdWp3W0GQR2LFVi=>
LXF-289 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwNEC0NFYh|ryP M1HQWXNCVkeURWK=
RL95-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwNEC1Olch|ryP NUX3RVI{W0GQR2LFVi=>
QIMR-WIL NGGyXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj1S3FKSzVyPUCuOFI3PzZizszN MXnTRW5IWkWU
K-562 NICybFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH6T3dYUUN3ME2wMlQ{PDd{IN88US=> NVL5c45KW0GQR2LFVi=>
NCI-H510A NHLYSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwNEO4NlMh|ryP M4qzXHNCVkeURWK=
NCI-H524 NHzaSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLUTWM2OD1yLkWxNVQ4KM7:TR?= MYXTRW5IWkWU
KE-37 NVG4RY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPGTWM2OD1yLkWyNVAzKM7:TR?= MmnzV2FPT1KHUh?=
KP-N-YS MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfYTWM2OD1yLkW0N|kzKM7:TR?= M3jhdHNCVkeURWK=
LS-411N M{fwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn4TmlKSzVyPUCuOVc4PTJizszN M3frV3NCVkeURWK=
CTV-1 M2nFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHSTWM2OD1yLkW4O|c{KM7:TR?= NF:1O2tUSU6JUlXS
NCI-SNU-16 M1y5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu0eWg3UUN3ME2wMlY{PTdzIN88US=> M3HoVnNCVkeURWK=
HT-144 Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;qTWM2OD1yLk[zO|k5KM7:TR?= NUOxXZNIW0GQR2LFVi=>
NCI-H187 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojXTWM2OD1yLk[0NVMh|ryP NWLjfJd[W0GQR2LFVi=>
OCI-AML2 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwNkS0NFMh|ryP MV\TRW5IWkWU
CCRF-CEM NXvxPGxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:0cXRKSzVyPUCuOlU{PDZizszN M1HET3NCVkeURWK=
ONS-76 M{\1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHsO2Z6UUN3ME2wMlY3PDV6IN88US=> M1fwXXNCVkeURWK=
IST-SL2 NXvjfXF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHy1d3ZKSzVyPUCuO|E6QDJizszN NHfwSJRUSU6JUlXS
NB6 NFfCZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[4fI1KSzVyPUCuO|czPTRizszN MYDTRW5IWkWU
SK-PN-DW MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwN{mxOEDPxE1? M4CxZXNCVkeURWK=
HCC1599 NVPoTFNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwOEC4O|Qh|ryP M1TWRnNCVkeURWK=
MC116 M{\MSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PafGlEPTB;MD64OVAyOSEQvF2= NY\Tb5ViW0GQR2LFVi=>
TE-15 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITYXGxKSzVyPUCuPFUxQThizszN NHHBPGtUSU6JUlXS
HOP-62 MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfUR2ROUUN3ME2wMlg3OzJ7IN88US=> NWPBPXVlW0GQR2LFVi=>
TGBC24TKB Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\kOWlEPTB;MD64OlM5PSEQvF2= NFHqTndUSU6JUlXS
HCE-4 NHO3cFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[5bGlEPTB;MD64PFA3OyEQvF2= Ml3QV2FPT1KHUh?=
ALL-PO NU\GRplXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rO[GlEPTB;MD64PFE4PSEQvF2= NHW2V2lUSU6JUlXS
KGN NWPqdWg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;YUGlEPTB;MD64PVk6PSEQvF2= Mn;2V2FPT1KHUh?=
ML-2 MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjFW25JUUN3ME2wMlkxOjV7IN88US=> M3;LUnNCVkeURWK=
ES4 M1vLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LicWlEPTB;MD65NVEzQCEQvF2= NU\0NHY3W0GQR2LFVi=>
SF126 NYHVO2pmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwOUS4NVkh|ryP Mn\oV2FPT1KHUh?=
SK-N-DZ MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvNTWM2OD1yLkm2NVg6KM7:TR?= MXvTRW5IWkWU
HCC1187 NH7WPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUewTllFUUN3ME2xMlAxPTB3IN88US=> M4TEc3NCVkeURWK=
DU-4475 M3q2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[5Vm57UUN3ME2xMlAyPzV4IN88US=> NXLufIExW0GQR2LFVi=>
NKM-1 M3S4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnXTWM2OD1zLkCyO|c2KM7:TR?= NVLIcG5QW0GQR2LFVi=>
HL-60 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXzTWM2OD1zLkC2OVc1KM7:TR?= M{n0PXNCVkeURWK=
SBC-1 NV3RWWY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;IW2hKSzVyPUGuNVI2PDJizszN NVXHOZgzW0GQR2LFVi=>
TE-10 M17lbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwMUK5OFYh|ryP NFG3R2pUSU6JUlXS
ETK-1 M1PnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrkRVU6UUN3ME2xMlE{PjF|IN88US=> MYLTRW5IWkWU
HAL-01 NYHQc29DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofjTWM2OD1zLkG2O|A6KM7:TR?= M2fDTHNCVkeURWK=
BB65-RCC NWP5NVJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXRZXp7UUN3ME2xMlE5ODB3IN88US=> MXTTRW5IWkWU
EW-1 NUC1ZWMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqwTWM2OD1zLkG4OVYzKM7:TR?= M1HGVXNCVkeURWK=
SK-NEP-1 M1zCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jmPWlEPTB;MT6yNVEyOSEQvF2= NW\rXWVYW0GQR2LFVi=>
SK-LMS-1 M4PENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2KyfGlEPTB;MT6yNlIyOiEQvF2= M2X4dnNCVkeURWK=
DEL M{DjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHHdnRzUUN3ME2xMlI2PjR|IN88US=> MX3TRW5IWkWU
GT3TKB M{TKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrp[Wh4UUN3ME2xMlI5ODV5IN88US=> NYTadHJnW0GQR2LFVi=>
MOLT-16 MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXJTWM2OD1zLkO1OFA2KM7:TR?= NEjKcmxUSU6JUlXS
CMK MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwNEKxNVch|ryP NUn5V41xW0GQR2LFVi=>
NB5 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPwc41KSzVyPUGuOlQzOjlizszN NUXnWFl7W0GQR2LFVi=>
NCI-H1963 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq4TWM2OD1zLkewOVg{KM7:TR?= M1HkbXNCVkeURWK=
KURAMOCHI NY\YVJExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\jTWM2OD1zLke4PVEyKM7:TR?= M{fpT3NCVkeURWK=
TE-8 M{jve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnGfmNCUUN3ME2xMlgxOzZ6IN88US=> MXrTRW5IWkWU
NCI-H1304 MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwOEOwO|Mh|ryP Ml3NV2FPT1KHUh?=
A101D MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXMTWM2OD1zLki3N|k2KM7:TR?= MUjTRW5IWkWU
SCLC-21H MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL2TWM2OD1zLkm3NFU4KM7:TR?= MnPmV2FPT1KHUh?=
GB-1 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonDTWM2OD1{LkCxOlQ4KM7:TR?= NGDG[2FUSU6JUlXS
KARPAS-45 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr4TWM2OD1{LkCyOlU1KM7:TR?= M2\tWnNCVkeURWK=
ATN-1 NF7L[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvKeW5KSzVyPUKuNFI5PThizszN M1zqVXNCVkeURWK=
NCI-H720 M{LXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJwME[yOFQh|ryP MXPTRW5IWkWU
RPMI-6666 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofKTWM2OD1{LkG2NlA4KM7:TR?= NVTP[VFFW0GQR2LFVi=>
NB17 NID4bVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\5[WlEPTB;Mj6yPVI4KM7:TR?= NX3NUFVqW0GQR2LFVi=>
IST-SL1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJwMkm3OlUh|ryP MUnTRW5IWkWU
SH-4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3myWGlEPTB;Mj6zNlQ3QSEQvF2= MU\TRW5IWkWU
K5 M3;WS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XoWmlEPTB;Mj60NFMyQSEQvF2= Mk\SV2FPT1KHUh?=
OVCAR-4 M2PPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLCWm1kUUN3ME2yMlQ3OTNizszN NH3TeZVUSU6JUlXS
ACN MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwNUCyNVMh|ryP MmHQV2FPT1KHUh?=
TGW MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC0TWM2OD1{Lk[1PFMzKM7:TR?= NIrJXHFUSU6JUlXS
NCI-H2107 NUXOd4ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrzem86UUN3ME2yMlg{PzFzIN88US=> MVfTRW5IWkWU
NCI-H82 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfONmNKSzVyPUKuPFM5OzhizszN NYWxSFJiW0GQR2LFVi=>
SK-N-FI NFXD[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj5bFUzUUN3ME2yMlg3QDZ6IN88US=> M1y0SHNCVkeURWK=
LB1047-RCC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK4TWM2OD1{Lki4NVI3KM7:TR?= MUjTRW5IWkWU
LU-134-A MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXmTWM2OD1{Lki5NlYh|ryP NVLlXGFSW0GQR2LFVi=>
NCI-H209 Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni1TWM2OD1{LkmxNlU{KM7:TR?= MYPTRW5IWkWU
NOMO-1 M2TaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTNwMEKyO|Qh|ryP NFjHfIhUSU6JUlXS
RH-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q1VGlEPTB;Mz6xO|I6OSEQvF2= NIHnZ|JUSU6JUlXS
LOUCY MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnuRZBKSzVyPUOuNVg3QTNizszN MVHTRW5IWkWU
TE-9 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTNwMk[3N|Yh|ryP NWKzPWRpW0GQR2LFVi=>
PF-382 M3nPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrPTWM2OD1|LkO1O|c5KM7:TR?= NH60XYJUSU6JUlXS
RPMI-8402 NWnRXJhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\ZOmJDUUN3ME2zMlU5PjB|IN88US=> MYTTRW5IWkWU
HEL M{\XeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNwNkOyJO69VQ>? NYm5Vo9pW0GQR2LFVi=>
NOS-1 Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInmXlFKSzVyPUOuPFQ4PTRizszN MV;TRW5IWkWU
ES1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjX[2k{UUN3ME2zMlkzOjl|IN88US=> MWPTRW5IWkWU
NCI-H2171 NWTPNGNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHLZYpkUUN3ME2zMlkzPDJ|IN88US=> NVqwe5VlW0GQR2LFVi=>
NCI-H747 NGfwcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTyRll[UUN3ME2zMlk1OjJzIN88US=> NF\mcY9USU6JUlXS
MHH-NB-11 NGjEN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTsNFhKSzVyPUOuPVU{OTJizszN MWPTRW5IWkWU
MZ1-PC M2K2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zmN2lEPTB;Mz65PVI1KM7:TR?= NHXFdINUSU6JUlXS
MMAC-SF NYHTOopKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH1[5ZKSzVyPUSuNFI1PjdizszN MnrpV2FPT1KHUh?=
NMC-G1 NIDGWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LET2lEPTB;ND6yNlczOyEQvF2= M2ryOnNCVkeURWK=
SW872 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPOTWM2OD12LkO0N|Qh|ryP MW\TRW5IWkWU
TE-12 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnrOJlYUUN3ME20MlU3Ozl2IN88US=> MVLTRW5IWkWU
LU-139 NXG3OHV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRwNkG4N|Uh|ryP M3LvTnNCVkeURWK=
HC-1 NVvIe5FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\Gb4pIUUN3ME20MlY6PDl2IN88US=> NIf4Z3pUSU6JUlXS
COR-L279 NYDxN49YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonVTWM2OD12Lke1PFkyKM7:TR?= NXL2XJRCW0GQR2LFVi=>
SF268 MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ZTWM2OD12Lke5PVE3KM7:TR?= NILxPVRUSU6JUlXS
MC-CAR M1r5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTVwME[3OVch|ryP NHHuPVhUSU6JUlXS
TK10 M4PmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTVwM{W0Olkh|ryP M4DTbnNCVkeURWK=
TE-1 NUSwO3lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vVS2lEPTB;NT60PVAxPCEQvF2= M3vyWnNCVkeURWK=
NCI-H2126 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTVwNkS1O|Qh|ryP MULTRW5IWkWU
Daudi NFP2foRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn2TWM2OD13Lk[5NVIh|ryP MkHrV2FPT1KHUh?=
NCI-H1648 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvxTWM2OD13LkixOFU1KM7:TR?= NHHa[o5USU6JUlXS
OS-RC-2 M2i4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHnTWM2OD13Lkm4OVk4KM7:TR?= NWDsW5JDW0GQR2LFVi=>
DJM-1 MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGy[Y9pUUN3ME22MlM1PjZ4IN88US=> NWLB[IZVW0GQR2LFVi=>
LS-1034 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLCTWM2OD14Lke1OlYh|ryP NXfjWW9EW0GQR2LFVi=>
NCI-H1581 NHS0cYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTZwN{i0NFUh|ryP NFO2W3dUSU6JUlXS
UACC-257 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz2VY5xUUN3ME23MlA1PTF{IN88US=> MULTRW5IWkWU
KM-H2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDSRmlpUUN3ME23MlE5PDV5IN88US=> NYTQ[pdjW0GQR2LFVi=>
NCI-H1436 M3PFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP3PFVKSzVyPUeuOlk6OzJizszN NXrITVYyW0GQR2LFVi=>
IA-LM MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi3fVJiUUN3ME23Mlg2QSEQvF2= NYHj[2kyW0GQR2LFVi=>
NCI-H526 NHLhTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRThwMkW2N|ch|ryP M4LtbHNCVkeURWK=
GCIY M4K1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fsZ2lEPTB;OD6zOlk3PSEQvF2= NYHQblBrW0GQR2LFVi=>
CP67-MEL M2ricWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjMTWM2OD16LkWzNlYh|ryP MW\TRW5IWkWU
KALS-1 NVTkTYxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRThwOEO4OVEh|ryP NW\tUnZqW0GQR2LFVi=>
NCI-H1770 NFXEdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLVfWNKSzVyPUiuPVAzPjVizszN Mn7EV2FPT1KHUh?=
8-MG-BA NGDZ[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC2PFFKSzVyPUmuN|I5PDRizszN NHrlW|lUSU6JUlXS
KY821 M{f3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTlwN{e0PFQh|ryP Ml7iV2FPT1KHUh?=
SNB75 NV;6dmVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXIVmJKSzVyPUGwMlA4PiEQvF2= NV73WphDW0GQR2LFVi=>
NCCIT MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe2eJhGUUN3ME2xNU4xPTh{IN88US=> M{[1b3NCVkeURWK=
SJSA-1 M4Dwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf3TWM2OD1zMT6yPFkyKM7:TR?= NHPhOHRUSU6JUlXS
LB373-MEL-D NX7le2x[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\aTlIyUUN3ME2xNU4{QDJ5IN88US=> M{LJdHNCVkeURWK=
TALL-1 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFzLkSwOVgh|ryP MX7TRW5IWkWU
NB69 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml75TWM2OD1zMT63O|A2KM7:TR?= NVq3O41vW0GQR2LFVi=>
NCI-H1355 M4TIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFzLkm0NlYh|ryP NGjqWY9USU6JUlXS
DMS-153 M4nkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTyW5NYUUN3ME2xNk4xPDJ4IN88US=> NHvTWGhUSU6JUlXS
OPM-2 NG\SSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HPTGlEPTB;MUKuNVU6PiEQvF2= NU\uXmk5W0GQR2LFVi=>
NB1 NFjrO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjCTG1KSzVyPUGyMlI6KM7:TR?= MYnTRW5IWkWU
A3-KAW NV\5cYdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDDTWM2OD1zMj6zNlM3KM7:TR?= Mne5V2FPT1KHUh?=
NCI-H1882 M4f4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXThcFZkUUN3ME2xNk41ODZ4IN88US=> MlnLV2FPT1KHUh?=
KG-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF{Lk[1OFUh|ryP M3frOnNCVkeURWK=
LC4-1 M1jFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF{Lke3NFYh|ryP MmXnV2FPT1KHUh?=
HCE-T NWTFemFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu5SFZKSzVyPUGzMlAxPDlizszN M1GwPHNCVkeURWK=
NEC8 MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLPTWM2OD1zMz6xNFM5KM7:TR?= NH\CfmJUSU6JUlXS
IST-MEL1 MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP6TWM2OD1zMz61O|g5KM7:TR?= NFfnVmZUSU6JUlXS
EW-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ftNGlEPTB;MUOuO|QxOiEQvF2= MWXTRW5IWkWU
CTB-1 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnGPWxKSzVyPUG0MlA{OjlizszN M1S0OXNCVkeURWK=
LS-123 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn3doJKSzVyPUG0MlE2QDhizszN MYDTRW5IWkWU
NCI-H1417 NHrQfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu4SYd1UUN3ME2xOE4{ODV{IN88US=> MoGzV2FPT1KHUh?=
MZ7-mel MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;KVWlEPTB;MUSuOFQ{OyEQvF2= NUn2S5MyW0GQR2LFVi=>
JiyoyeP-2003 M2q3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37ONmlEPTB;MUWuOlMzPiEQvF2= MUjTRW5IWkWU
ES6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7Hb2ZKSzVyPUG2MlI{PjFizszN NVnIPJR6W0GQR2LFVi=>
HH NFLTbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfUeVRmUUN3ME2xO{4yQTZ|IN88US=> NILiOWZUSU6JUlXS
SF539 M1vjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInpTGZKSzVyPUG3Mlk6OjJizszN NYnjd5JZW0GQR2LFVi=>
Calu-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzLcXpTUUN3ME2xPU4zOzlizszN NGLlNFBUSU6JUlXS
SK-MM-2 M2niXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLCd2U5UUN3ME2xPU42PTVizszN MmDSV2FPT1KHUh?=
IST-MES1 NWHVeWtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[0TWM2OD1zOT62OlY{KM7:TR?= MoDQV2FPT1KHUh?=
GI-ME-N NFvhSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vkWmlEPTB;MUmuPFIzPyEQvF2= M3\TcHNCVkeURWK=
CAL-148 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;jTWM2OD1{MD65PVM1KM7:TR?= NY\ZRYZnW0GQR2LFVi=>
EVSA-T MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXhTWM2OD1{MT6xOFk6KM7:TR?= NYfIenozW0GQR2LFVi=>
LP-1 NYXiUWJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fGdGlEPTB;MkGuN|Q{OiEQvF2= Moj2V2FPT1KHUh?=
BOKU NGDCTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jNcWlEPTB;MkGuOFU{OyEQvF2= NX32TZRFW0GQR2LFVi=>
KLE M172OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ{LkG5NFMh|ryP MVjTRW5IWkWU
LB831-BLC NW\wfW95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;KTWM2OD1{NT6xOVI3KM7:TR?= NGK0SFBUSU6JUlXS
NCI-H889 M1TiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\CbG9KSzVyPUK1MlE6OzFizszN NVLCdIFmW0GQR2LFVi=>
REH M3XWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ3LkS2O|Eh|ryP NXP6R4p{W0GQR2LFVi=>
KP-N-RT-BM-1 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fpW2lEPTB;MkWuOFc2OiEQvF2= M3TubnNCVkeURWK=
MPP-89 NIrzRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ3LkWzNVQh|ryP MoDmV2FPT1KHUh?=
no-11 NFfQU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPLSI5KSzVyPUK1Mlc1PyEQvF2= M{PVfnNCVkeURWK=
NCI-H748 NInyXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPDbGY1UUN3ME2yOU44PjJ5IN88US=> NUfWXlRZW0GQR2LFVi=>
LB2518-MEL MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ5LkG3O|Mh|ryP M17TTHNCVkeURWK=
TGBC1TKB MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO0Z5QzUUN3ME2yO{42PTh3IN88US=> NF7XUWZUSU6JUlXS
MHH-PREB-1 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjFTWY3UUN3ME2yPE4xPzN2IN88US=> NXLxdJNTW0GQR2LFVi=>
MZ2-MEL NEPO[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zH[mlEPTB;MkiuOlE1OyEQvF2= M4DrdHNCVkeURWK=
U-266 MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF31dYRKSzVyPUK4MlY{PjZizszN NEnaVFlUSU6JUlXS
SNU-C1 MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvJXpdWUUN3ME2yPE46PDNizszN MXHTRW5IWkWU
SW962 NFfId4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTNyLkK3OFch|ryP MnKyV2FPT1KHUh?=
Raji MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\qTWM2OD1|MD61OVkzKM7:TR?= MX3TRW5IWkWU
KNS-42 NHvmXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEexT3RKSzVyPUOwMlg6PTZizszN MkLkV2FPT1KHUh?=
LB996-RCC MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljLTWM2OD1|MT6xO|AzKM7:TR?= NHvuNWJUSU6JUlXS
CHP-126 MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy2WYZKSzVyPUOxMlE6QDRizszN MkLsV2FPT1KHUh?=
RXF393 NUXDeG9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTN{LkS5O{DPxE1? NHvrRW5USU6JUlXS
COLO-684 NHi2emlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rpO2lEPTB;M{KuOlQ{QCEQvF2= MX7TRW5IWkWU
A704 M{Dzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTN|LkW1N|gh|ryP MoDRV2FPT1KHUh?=
A253 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTN|LkW4OVIh|ryP NXnmZlZHW0GQR2LFVi=>
KNS-81-FD NIjlb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7adotKSzVyPUO0MlU1PTZizszN Mn7GV2FPT1KHUh?=
TE-441-T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\NTWM2OD1|ND62N|cyKM7:TR?= NXvxRYk2W0GQR2LFVi=>
HCC2157 NWXYPYdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTN3LkS2NVkh|ryP NIfC[GpUSU6JUlXS
ES3 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rqRmlEPTB;M{[uOlc2KM7:TR?= MlnzV2FPT1KHUh?=
NCI-H1155 M{fhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fxcGlEPTB;M{euPFE2KM7:TR?= NELtVXZUSU6JUlXS
SNU-C2B MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:zOplKSzVyPUO4MlE3PTRizszN MVXTRW5IWkWU
JAR NHTMfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN6LkK0OFkh|ryP M{fSdnNCVkeURWK=
GDM-1 NHj6TXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK1Nml{UUN3ME2zPE46OTF4IN88US=> NYTGRVJnW0GQR2LFVi=>
KU812 M{S0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW2TWM2OD12MT61NFch|ryP NIjNZ3dUSU6JUlXS
BC-1 NID5b2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrFeWhKSzVyPUSyMlY4OzFizszN NXzNW3FJW0GQR2LFVi=>
GI-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS3TWM2OD12Mj65NVkzKM7:TR?= MVPTRW5IWkWU
NCI-H1694 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HEd2lEPTB;NESuPVQ4OiEQvF2= MnnNV2FPT1KHUh?=
DG-75 NFf4PGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfrdZU6UUN3ME20OU4yPTd5IN88US=> NX3aOGx[W0GQR2LFVi=>
COR-L88 NXrrPHplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3KfYZKSzVyPUS1MlI4PzhizszN NFLn[XJUSU6JUlXS
LS-513 M1j0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nBWGlEPTB;NEWuPVE2PiEQvF2= NVPQSFhZW0GQR2LFVi=>
HD-MY-Z Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf4OFUyUUN3ME20Ok41PjF{IN88US=> MnPqV2FPT1KHUh?=
L-363 NVrTUWFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTR4Lki4NUDPxE1? MXLTRW5IWkWU
TE-6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17RemlEPTB;NEiuOFQ3KM7:TR?= MmezV2FPT1KHUh?=
NCI-H345 M3PUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PISmlEPTB;NEiuOFY5KM7:TR?= MXrTRW5IWkWU
TE-5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXJT3hJUUN3ME20PU44OTF6IN88US=> NX;VWphvW0GQR2LFVi=>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
DLK / p-MKK7 / MKK7 / p-JNK / JNK ; 

PubMed: 23431148     


Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. 

p-AURKA / AURKA / Survivin ; 

PubMed: 28218735     


BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. 

YAP; 

PubMed: 31160567     


Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. 

p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; 

PubMed: 21600017     


NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.

23431148 28218735 31160567 21600017
Immunofluorescence
α-tubulin / Aurora-A ; 

PubMed: 21600017     


The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.

21600017
Growth inhibition assay
Cell viability; 

PubMed: 21600017     


VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, *p < 0.05, **p < 0.01, compared to control.

21600017
In vivo VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. [1]

Protocol

Kinase Assay:

[3]
- Collapse

Kinase inhibition assays:

The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl2, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K i = IC50 / (1 + [S]/Kd), where [S] = [ATP] = 2.2 mM, and Kd (of ATP to Abl) = 70 μM. These values are calculated assuming a Kd (ATP) of 70 μM for wild type and H396P Abl kinase domain.
Cell Research:

[2]
- Collapse
  • Cell lines: CAL-62 cells
  • Concentrations: 5-500 nM
  • Incubation Time: 4 days
  • Method:

    The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500  nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500  nM). The cells are pulse labeled with 30  mM BrdU for 2  hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control.


    (Only for Reference)
Animal Research:

[1]
- Collapse
  • Animal Models: Female athymic NCr-nu mice bearing HL-60 leukemia cells
  • Dosages: 50 mg/kg, 75 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (200.17 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing. 		15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.59
Formula

C23H28N8OS
CAS No. 639089-54-6
Storage powder
in solvent
Synonyms N/A
Smiles CC1=CC(=NN1)NC2=CC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)C4CC4)N5CCN(CC5)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

  • Pan Aurora Kinase Inhibitors

    Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.

  • Pan Aurora Kinase Inhibitors

    SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.

  • Most Potent Aurora Kinase Inhibitor

    MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.

  • Aurora Kinase Inhibitor in Clinical Trial

    Alisertib (MLN8237) : Phase III for Relapsed/Refractory Peripheral T-Cell Lymphoma.

  • Classic Aurora Kinase Inhibitor

    Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.

  • CCG-1423 New

    CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.

  • ML141 New

    ML141 (CID-2950007) is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 is associated with an increase in p38 activation and may induce p38-dependent apoptosis/senescence. ML141 also protects neuroblastoma cells from metformin-induced apoptosis.

  • Alisertib (MLN8237)

    Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Alisertib induces cell cycle arrest, apoptosis and autophagy. Phase 3.

    Features:First orally available inhibitor of Aurora A.

  • Barasertib (AZD1152-HQPA)

    Barasertib (AZD1152-HQPA, AZD2811) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.

  • Danusertib (PHA-739358)

    Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Danusertib induces apoptosis, cell cycle arrest, and autophagy. Phase 2.

  • ZM 447439

    ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

    Features:An Aurora selective ATP-competitive inhibitor.

  • MLN8054

    MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.

  • MK-5108 (VX-689)

    MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. MK-5108 (VX-689) induces autophagy. Phase 1.

  • Aurora A Inhibitor I (TC-S 7010)

    Aurora A Inhibitor I (TC-S 7010) is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B. Aurora A Inhibitor I (TC-S 7010) triggers apoptosis through the ROS-mediated UPR signaling pathway.

    Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Tags: buy Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) supplier | purchase Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) cost | Tozasertib (VX-680, MK-0457) manufacturer | order Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID